RenalWEB Home Page
Last Updated 10/22/17
   
   

PubMed Searches

Inflammation - The Silent Problem in ESRD
by Thomas F. Parker III, MD

Mortality in ESRD patients far exceeds anything acceptable. Vast improvements in the delivery of care in ESRD (end-stage renal disease) have only translated to modest improvements in mortality outcomes. Consider enhancements in membranes, quantity of dialysis, anemia and iron control, social services, intradialytic symptom control, and many, many others. Why has there not been a commensurate improvement?

Perhaps there is a fundamental underlying cause of morbid and mortal events which the nephrology community now understands more lucidly.

The following, simplistically, presents an overview of the problem.

The story starts long before patients develop ESRD.

  • Patients with chronic renal insufficiency begin to develop anemia that is more than just erythropoeitin deficiency. It seems to be an anemia, in part, like ones seen in chronic inflammatory states, such as rheumatoid arthritis.
  • Patients begin to eat less protein. And the albumin drops. But experts tell us that one almost has to starve in order to decrease protein synthesis just from a dietary protein intake. Why do pre-ESRD patients begin to eat less and why does albumin decrease, disproportionately, along with other visceral protein markers.
  • Then creatinine excretion begins to decrease, suggesting that somatic protein stores are decreasing. And this when dietary protein intake should be sufficient to maintain somatic stores.
  • Iron metabolism changes, again like that of other chronic disease states.
  • And cardiovascular disease becomes more prevalent, with increased atherosclerosis and left ventricular disease, disproportionate to what one would expect from the associated lipid disorders, hypertension, and volume control - though these are often poorly controlled.

An underlying trend and possible binding pattern begins to emerge and we are provoked to pause and query: Is there an underlying common process which is the provocateur?

Then ESRD, with associated renal replacement therapy follows, and all of the above entities and others seem to accelerate. Patients begin to die of an assortment of cardiovascular diseases, infections, access thromboses, rapidly deteriorating residual renal function, bone disease associated with "amyloid" deposits, visceral protein depletion uncorrected by dietary intervention, lessening muscle mass, vastly abnormal iron metabolism, and the list goes on.

Broadly speaking, it may indeed be possible to put this into a common pattern, a common inciting process. I believe that underlying all of these clinically observed problems is the indolent process of CHRONIC INFLAMMATION. Patients become increasingly "inflamed" as preESRD worsens, and then the inflammatory process is probably augmented by components of renal replacement therapy.

We know that they are inflamed because there are markers of inflammation: high levels of cytokines, markers of positive and negative and acute phase reactions, and disease patterns which are characteristic of inflammation emerge, just for starters.

Allow the following pictorial concept:

Many diseases result in the Systemic Inflammatory Response (SIR).

(Ed. note: TNF is tumor necrosis factor. Interleukin-1, interleukin-6 and tumor necrosis factor are three pro-inflammatory cytokines, mainly produced by monocytes. Definitions are from mondofacto.)

And there is a certain common pattern that results. Once the SIR has begun, it can manifest itself in a positive or negative manner:

Positive manner:

(Ed. note: Definitions for : hemostasis, phagocytosis, proteolytic, antimicrobial, antioxidant, and antithromboticfrom mondofacto.)

Negative manner:

Note that the manifestations of this SIR are many of the clinical phenomenon of ESRD patients: changes in albumin, transferrin, hemostasis, accumulation of macroglobulins, etc.

ESRD is associated with SIR. But, perhaps, so is renal replacement therapy. The very therapy that is necessary for removal of solute and water, though highly successful in accomplishing this, may be provoking the inflammatory process more so. Possibilities would include:

  • Exposure to "contaminants" and bioincompatible materials in
    • membranes and other materials of the dialyzer
    • dialysis solution (water and concentrate)
    • tubing
  • Recurrent access punctures and manipulations
  • Recurrent hypotensive episodes
  • Hypervolemia
  • Recurrent infections and antibiotics
  • And on and onů.

All of these could be and/or have been demonstrated to be associated with cytokine release with resulting cascade of inflammatory processes.

So the overall picture looks something like this:

The pre ESRD patient has an ongoing inflammatory process, which may or may not be aggravated by diabetes or congestive heart failure or infection. Then renal replacement therapy is imposed which is pro-inflammatory. The cascade of events results in all of the disease entities we see each day in the dialysis setting, ending in death.

The picture that emerges is an ESRD patient who has an underlying permeating inflammatory disease that ultimately results in an unrelenting decline in health. I have omitted the evidence that confirms that the ESRD has markers of inflammation. I have further omitted those data showing the relationship of inflammation to the progression of cardiovascular disease and other clinical conditions seen in the ESRD population. And, I have omitted showing the relationship of inflammatory markers to morbidity and mortality.

Renal replacement therapy prolongs life for a modest duration. At the same time, though, we may be aggravating the inflammatory response and accelerating the ultimate outcome. We clearly must move beyond thinking of treating solute and water removal and correction of obvious manifestations of renal failure such as anemia, bone disease, and other metabolic changes. We must begin to search out and correct the permeating and pervasive inflammatory process.

February 2000

Warning:  Changes should never be made in a patient's treatment or care based solely on the information found here.  Every patient has unique healthcare concerns and considerations and all these factors must all be taken into account before any changes can be safely made.  All medical and therapeutic decisions must come from a qualified health care provider.  Read RenalWEB's Legal Disclaimer before proceeding.


  NEWS & LATEST ARTICLES
blue ball

Plasma High Sensitivity Troponin T Predicts End-Stage Renal Disease and Cardiovascular and All-Cause Mortality in Patients with Type I Diabetes and Diabetic Nephropathy - Free, Full-Text Article from Kidney International. - November 2017

blue ball

Aldosterone Antagonist Therapy and Its Relationship with Inflammation, Fibrosis, Thrombosis, Mineral Bone Disorder and Cardiovascular Complications in Peritoneal Dialysis (PD) Patients - Free, Open Access article from International Urology and Nephrology. - October 2017

blue ball

Complement Activation in Peritoneal Dialysis–Induced Arteriolopathy - JASN Express abstract. - October 18, 2017

blue ball

Residual Renal Function in Hemodialysis and Inflammation - Early View abstract from Therapeutic Apheresis and Dialysis. - October 3, 2017

blue ball

Predictive Value of Procalcitonin for Diagnosis of Infections in Patients with Chronic Kidney Disease: a Comparison with Traditional Inflammatory Markers C-Reactive Protein, White Blood Cell Count, and Neutrophil Percentage - First Online Abstract from International Urology And Nephrology. - September 30, 2017

blue ball

Mortality Prediction in Stable Hemodialysis Patients Is Refined by YKL-40, a 40-kDa Glycoprotein Associated with Inflammation - Article in Press abstract from Kidney International. - September 30, 2017

blue ball

Baxter Launches First 3-In-1 Set For Use in Continuous Renal Replacement Therapy and Sepsis Management Protocols - Press release. - September 26, 2017

blue ball

Body Composition and Inflammation in Hemodialysis Patients - Early View abstract from Therapeutic Apheresis and Dialysis. - September 22, 2017

Top of Page


  WEB RESOURCES
blue ball Latest Scientific Journal Articles on Inflammation
Mechanisms of Chronic Inflammation and Immunopharmacological Intervention web site - maintained by Heinfried H. Radeke - Research at the Medical School of Hannover - Germany
A Debate on the Metabolic Syndrome: Evolving Challenges and Controversies from the Medscape web site (free subscription required)
On-line medical dictionary  with cross-reference links
Top of Page


  PUBMED SEARCHES (National Library of Medicine's MEDLINE Database)
sterile dialysate and hemodialysis
homocysteine and dialysis
systemic inflammatory response syndrome
systemic inflammatory response syndrome AND hemodialysis
cytokine AND hemodialysis
interleukin-6 AND hemodialysis
tumor necrosis factor (TNF) and dialysis
MEDLINE / Pubmed Information from the National Library of Medicine
Top of Page


  RELATED NEWS & TOPICS
January 30, 2001 - The National Institute on Aging (NIA) announced today that researchers have launched a multi-site trial nationwide to determine whether certain nonsteroidal anti-inflammatory drugs (NSAIDs) actually slow the cognitive decline in patients with Alzheimer's disease.
January 10, 2008 - Reversal Of Alzheimer's Symptoms Within Minutes - article from Medical News Today


  DISCUSSION FORUM
General Dialysis Nursing Issues and Questions (No dedicated RenalWEB forum)
Top of Page


  INPUT / SUGGESTIONS
E-mail to RenalWEB on the Inflammation Topic
Top of Page

 

 

Except where noted, no information within the RenalWEB web site can be copied, duplicated, or reproduced in any form without the express written consent of RenalWEB.